Featured Story | By Annalee Armstrong Pfizer has had plenty of success in respiratory syncytial virus lately, with multiple FDA designations and clinical advancements for its vaccine candidate. But that’s not enough for the pharma giant. Today, the New York-based behemoth is acquiring ReViral and its collection of therapeutics for the pesky respiratory virus for $525 million. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Jazz Pharmaceuticals and Werewolf Therapeutics will work together in a new $15 million upfront, backloaded biobucks deal that covers a preclinical oncology candidate that goes after difficult and unresponsive tumors. read more By Nick Paul Taylor AstraZeneca has joined the swarm of biotechs targeting Claudin18.2 (CLDN18.2). In return for $25 million upfront and more on the back end, the Big Pharma has landed worldwide rights to Harbour BioMed’s bispecific, positioning it to fight for a market targeted by Amgen, Astellas, BioNTech and more. read more Sponsored by: Evidation Health Evidation and BARDA researchers were able to directly recruit subjects for a COVID-19 study via mobile app, & create an AI risk model, while recruiting a representative cohort. read more By Annalee Armstrong Moderna is turning its mRNA tech to even more global health challenges through a partnership with nonprofit research organization IAVI. The collaboration will focus on developing vaccines and antibodies for HIV/AIDS, tuberculosis, antimicrobial-resistant enteric infections and of course COVID-19. read more By Nick Paul Taylor Ark Biopharmaceutical’s bet on one of the less congested parts of the respiratory syncytial virus (RSV) space has delivered phase 3 results. Having picked up an antiviral prospect from Roche, ArkBio has now reported a late-phase study in infants hospitalized with RSV has met its primary endpoint. read more By Gabrielle Masson Gilead has unveiled a new global pediatric drug development center in Ireland, which will have 33 job openings by the end of 2022. read more By Max Bayer Takeda spinout HilleVax filed for a $100 million IPO Wednesday, a test of the choppy public waters after a bear market tortured biotechs for much of 2021. The company believes its norovirus vaccine candidate could be a winner as it prepares to launch a phase 2 trial in infants. read more By Max Bayer Healthcare data behemoth IQVIA has been building up machine learning, but it's not yet a "golden egg," says Gary Shorter, the company's head of AI and data science. Instead, it's in "incubation," with efforts to expand ongoing as the software is refined. read more By Kevin Dunleavy Boehringer Ingelheim has earmarked more than 7 billion euros ($7.6 billion) for capital investments through 2025, the company revealed in its annual report on Tuesday. The splurge comes after BI cut the ribbon on a 700 million euro ($757 million) plant in Vienna in October. read more By Heather Landi The more restrained digital health funding numbers in the first quarter may reflect investor caution, according to the report, with the rise-and-fall of COVID variants, energy shocks, market volatility, the dismal performance of public digital health companies and inflation numbers signaling choppy waters for digital health investors. read more By Andrea Park Within four years, the Israeli startup has racked up nine nods from the FDA, the latest for an AI tool designed to automatically identify potential cases of brain aneurysm in head CT scans. read more By Gareth Macdonald Charles River Laboratories has acquired contract vivarium services firm Explora BioLabs in a $295 million deal designed to expand its preclinical research business. read more By Gareth Macdonald Trial technology and review services firm WCG says its strategic partnering scheme will help CROs avoid delays relating to limited trial site capacity. read more Resources Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Medidata, a Dassault Systèmes company The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
